Form 4: IGM Biosciences Director Behrens M Kathleen Reports Stock Transactions

Director Kathleen Behrens reports acquisition of 3,078 shares of IGM Biosciences common stock and disposal of 13,124 shares.

Summary

• On June 28, 2024, Kathleen Behrens, a director of IGM Biosciences, reported acquiring 3,078 shares of common stock.
• These shares were received as fully vested restricted stock units (RSUs), representing a quarterly retainer payment under the company's Outside Director Compensation Policy.
• The director also disposed of 13,124 shares of common stock.
• Following these transactions, Behrens directly owns 13,124 shares.
• Additionally, Behrens indirectly owns 330,700 shares as trustee of KBW 2005 Trust, 29,807 shares as trustee of Non-Exempt Trust for Patrick R. Wilsey, and 29,806 shares as trustee of Non-Exempt Trust for Shannon K. Wilsey.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing primarily reports routine stock transactions. The acquisition of shares via RSUs is mildly positive, while the disposal is mildly negative, balancing out to a neutral overall sentiment.

Positives

• The acquisition of shares via RSUs indicates continued alignment of the director's interests with those of the company and its shareholders.

Negatives

• The disposal of 13,124 shares could be interpreted negatively, although the reason for disposal is not specified.

Risks

• The Form 4 filing itself doesn't inherently present risks, but monitoring insider transactions is crucial for assessing potential shifts in sentiment or strategic direction.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and are closely watched by investors for signals about company performance and management's confidence.

Stakeholder Impact

• Shareholders may be interested in the director's stock transactions as an indicator of confidence in the company's future prospects.

Key Dates